Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GB-5267

Cell therapy (CAR-T) · Kills target cells, directed at membrane-bound mucin-16 (MUC16, CA125) (MUC16)

Phase 1 Most advanced trial
1 Registered trials

What is GB-5267?

GB-5267 is an autologous T-lymphocyte cell therapy genetically modified to express an anti-MUC16 chimeric antigen receptor with 4-1BB and CD3zeta signaling domains, and to secrete interleukin 18. The engineered cells recognize membrane-bound MUC16 on tumor cells and kill them, and are being studied in platinum-resistant ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
membrane-bound mucin-16 (MUC16, CA125) (MUC16) (antigen)
Mechanism
Kills target cells, directed at membrane-bound mucin-16 (MUC16, CA125) (MUC16)
Pathways
T-cell activation, proliferation and persistence, immune response against tumor cells
Therapy area
Oncology
In trials of
GENB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07489287 Phase 1 Platinum-resistant Ovarian Cancer Recruiting GENB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Platinum-resistant Ovarian Cancer

Other drugs acting on MUC16

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.